Lv4
458 积分 2023-06-26 加入
慢性骨髄性白血病の最新の知見と治療の進歩
2天前
待确认
Population pharmacokinetic modeling of asciminib in support of exposure-response and ethnic sensitivity analyses in patients with chronic myeloid leukemia
3天前
已完结
HRS-5965, a small-molecule factor B inhibitor, in healthy participants and participants with renal insufficiency: A first-in-human, phase 1 trial
3天前
已完结
The Combination of Zidovudine and Interferon AIpha-2B in the Treatment of Adult T-Cell Leukemia/Lymphoma
8天前
已完结
Four versus Two Years of Rituximab Maintenance (R-Maintenance) Following Bendamustine Plus Rituximab (B-R): Results of a Prospective, Randomized Multicenter Phase 3 Study in First-Line Follicular Lymphoma (the StiL NHL7-2008 MAINTAIN Study)
10天前
已完结
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
10天前
已完结
Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: Nine-year updated results from the StiL NHL1 study
10天前
已关闭
Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma
10天前
已完结
Quality-of-life endpoints collection, reporting, and framing in randomised trials of indolent lymphomas: a systematic review
10天前
已完结
Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study
16天前
已完结
皖公网安备34019202002308
